Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer

Urology

Volumn 61, Issue 6, 2003, Pages 1261-1265

  Hlavaty, John J ^b   Partin, Alan W ^c   Shue, Matthew J ^c   Mangold, Leslie A ^c   Derby, Jennifer ^c   Javier, Teofilo ^c   Kelley, Shane ^c   Stieg, Adam ^c   Briggman, Joseph V ^c   Hass, G Michael ^a   Wu, Ying Jye ^c  

^a Matritech Inc   (United States)

^b CURAGEN CORPORATION   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEIN NMP48; TUMOR MARKER; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN;

ARTICLE; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DNA FINGERPRINTING; EARLY DIAGNOSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MASS SPECTROMETRY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN ANALYSIS; PROTEIN PURIFICATION; STATISTICAL SIGNIFICANCE;

EID: 0037602058     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00036-0     Document Type: Article

References (19)

1. National Cancer Institute. CancerNet PDQ Cancer Information Summaries. Screening for Prostate Cancer.http:cancer.gov/cancer_information/cancer_type/prostate/Viewed January 28, 2002.
2. Stanford J.L., Stephenson R.A., Coyle L.M., et al. Prostate Cancer Trends 1973-1995. 1999;SEER Program (National Cancer Institute), Bethesda.
3. Catalona W., Richie J., Ahmann F., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer results of a multicenter clinical trial of 6,630 men. J Urol. 151:1994;1283-1290.
4. Polascik T.J., Oesterling J.E., Partin A.W. Prostate specific antigen a decade of discovery - what we have learned and where we are going. J Urol. 162:1999;293-306.
5. Carroll P., Coley C., McLeod D., et al. Prostate-specific antigen best practice policy. Part 1. Early detection and diagnosis of prostate cancer. Urology. 57:2001;217-224.
6. Council on Scientific Affairs, Screening and Early Detection of Prostate Cancer. Chicago, American Medical Association, 2001. Available at: http://www.ama-assn.org/ama/pub/article2036-4438.html. Accessed January 28, 2002.
7. Smith R., von Eschenbach A.C., Wender R., et al. American Cancer Society Guidelines for the Early Detection of Cancer update of early detection guidelines for prostate, colorectal, and endometrial cancers, and update 2001: testing for early lung cancer detection. CA Cancer J Clin. 51:2001;38-75.
8. Barry M. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med. 344:2001;1373-1377.
9. Hlavaty J., Partin A.W., Kusinitz K. Mass spectroscopy as a discovery tool for identifying serum markers. Clin Chem. 47:2001;1924-1926.
10. Watkins B, Szaro R, Ball S, et al: Detection of early stage cancer by serum protein analysis. American Laboratory, June 2001.
11. Shevchenko A., Wilm M., Vorm O., et al. Mass spectrometric sequencing of proteins from silver stained gels. Analytic Chem. 68:1996;850-858.
12. Perkins D.N., Pappin D.J., Creasy D.M., et al. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis. 20:1999;3551-3567.
13. Gann P.H., Ma J., Hennekens C.H., et al. Circulating vitamin D metabolites in relationship to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev. 5:1996;121-126.
14. Cooke N.E., Haddad J.G. Vitamin D binding protein (Gc globulin). Endocrin Rev. 10:1989;294-307.
15. Verboyen C., Rabijns A., DeMaeyer M., et al. A structural basis for the unique binding features of the human vitamin D binding protein. Nat Struct Biol. 9:2002;131-136.
16. Williams M.H., Van Alstyne E.L., Galbraith R.M. Evidence of a novel association of unsaturated fatty acids with Gc (vitamin D binding protein). Biochem Biophys Res Commun. 153:1988;1019-1024.
17. Bouillon R, Van Baelen H, DeMoor P: Physiology and pathophysiology of vitamin D binding protein, in Forest MG, Pugeat M (Eds): Binding Proteins of Steroid Hormones. Coedited by INSERM/John Libbey Eurotext. Collection Vol. 149, p 347, 1986.
18. Yamamoto N., Homma S. Vitamin D3 binding protein (group specific component, Gc) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Nat Acad Sci USA. 88:1966;8539-8543.
19. Lees A., Haddad J.G., Lin S. Brevin and vitamin D binding protein comparison of the effects of two serum proteins on actin assembly and disassembly. Biochemistry. 23:1984;3038-3047.